How would you treat a patient with metastatic clear cell renal cancer who has progressed on immunotherapy and developed bleeding on cabozantinib?   

Given antiangiogenic activity, is any TKI an option? 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at The Oncology Institute of Hope and Innovation
Thank you. 
Sign in or Register to read more